Evotec SE — AGM Information 2014

Jun 17, 2014

News Details

Corporate | 17 June 2014 16:57

Resolutions of the Annual General Meeting of Evotec AG

DGAP-News: Evotec AG / Key word(s): AGM/EGM

17.06.2014 / 16:57

---

• Actions of Management Board and Supervisory Board approved
• New Supervisory Board elected: Prof. Dr Wolfgang Plischke new Chairman of
  the Supervisory Board
• Authorised Capital 2014 created

Hamburg - 17 June 2014: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX,
ISIN: DE0005664809) today announced that its shareholders approved all
proposals the Company's Management put to vote at the Company's Annual
General Meeting.

The Chief Executive Officer of Evotec AG, Dr Werner Lanthaler, presented
the Company's performance for the year 2013 and provided the shareholders
with an update on the topic "Execute & Innovate 20 years of Research - 20
years of Evotec".

At the Annual General Meeting, the actions of the members of the Management
Board and the Supervisory Board for the fiscal year 2013 were approved.
Furthermore, a new Supervisory Board was elected by the Annual General
Meeting. The term of the new Supervisory Board ends with the close of the
Annual General Meeting charged with approving the actions of the members of
the Supervisory Board in the 2018 fiscal year. Prof. Dr Wolfgang Plischke,
former member of the Management Board of Bayer AG, Prof. Dr Iris
Löw-Friedrich, Chief Medical Officer and Executive Vice President of UCB
S.A., and Prof. Dr Paul Linus Herrling, former global Head of Research of
Novartis Pharma AG and Chairman of the Board of the Novartis Institute for
Tropical Diseases joined the Supervisory Board as new members. Three former
members of the Supervisory Board, Dr Walter Wenninger, Dr Claus Braestrup
and Bernd Hirsch, were re-elected as members of the new Supervisory Board
of Evotec.

In a subsequent meeting of the Supervisory Board, Prof. Dr Wolfgang
Plischke was elected as Chairman of the Supervisory Board and Dr Walter
Wenninger, former Chairman of the Supervisory Board of Evotec, was elected
as his Vice Chairman.

"I'd like to express my sincere gratitude to the parting members of the
Supervisory Board, Mary Tanner, Roland Oetker and Prof. Dr Andreas
Pinkwart, also on behalf of my colleagues in the Management Board, for
their constructive and successful collaboration over the last years", said
Dr Werner Lanthaler, Chief Executive Officer of Evotec. "At the same time,
I'd like to thank the remaining members of the Supervisory Board for their
continued commitment and warmly welcome Prof. Dr Iris Löw-Friedrich, Prof.
Dr Wolfgang Plischke and Prof. Dr Paul Linus Herrling to the Supervisory
Board of Evotec AG."

The Annual General Meeting also approved the proposal of the Management
Board and the Supervisory Board to create a new Authorised Capital 2014.
Moreover, the Annual General Meeting passed the other agenda items
requiring shareholders' approval, hereunder the resolution on single
amendments of the Articles of Association and the appointment of Ernst &
Young GmbH Wirtschaftsprüfungsgesellschaft, Hamburg, as the auditor for
fiscal year 2014.

At the ordinary Annual General Meeting 2014 of Evotec AG, 34.9% of the
voting capital was present.

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com

End of Corporate News

---

17.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart

End of News DGAP News-Service

274089 17.06.2014